All U.S. healthcare stakeholders recognize that the overheated drugs market is not sustainable. The ever-growing spiral of rising gross prices, often accompanied by increasing rebates and returns, is not a model fit for purpose now, let alone the future.

National and regional payers identify the real-world advantages of innovative contracts